BioPharma Resources

Drug Trial Radar · NCT04521179

Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors

A Phase II, Open-Label, Multi-Center Study to Evaluate Efficacy, Safety and Tolerability of KN026 in Combination With KN046 in Patients With Locally Advanced Unresectable or Metastatic HER2-positive Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

102

Actual

Start

Dec 7, 2020

Primary completion

Jan 12, 2022

Study completion May 22, 2023

Sponsor

Sponsor type
Industry
Collaborators
Peking University
First posted
Aug 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, phase II,multi-center study to evaluate the efficacy, safety and tolerability of KN026 in combination with KN046 in subjects with HER2-positive solid tumors.

Conditions

  • HER2-positive Solid Tumors

Interventions

  • KN026 combinationDrug

    30 mg/kg Q3W KN026+ 5 mg/kg Q3W KN046

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR )Time frame: Throughout the duration of the study; up to 2 years
  2. Duration of response (DOR)Time frame: Throughout the duration of the study; up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.